Becton, Dickinson and Company (BDX) Earnings

Becton, Dickinson and Company

BDX · NYSE

Jun 2026upcoming

Next quarter

Consensus is $3.14 EPS for Jun 2026 across 6 estimates, ranging $3.06 to $3.22.

BDX Mar 2026

Reported May 7, 2026

Beat 4.69%

EPS estimate: $2.77
EPS actual: $2.90
Revenue estimate: —
Revenue actual: —
1-day move: -2.50%

Call highlights have not been generated for this quarter.

Symbol: BDX
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare.

Key Issues

Bullish view

Revenue increased to $21.8 billion in FY2025 from $20.2 billion in FY2024, and the upcoming quarter is receiving detailed estimate scrutiny from Zacks. That creates a potential foundation for stronger results if operating metrics improve.

Bearish view

Net income remained at $1.7 billion in both fiscal years despite the revenue increase. The supplied evidence provides no indication that profitability is accelerating.

Analyst Consensus

See all

Hold

16 analysts

$169

Current

—

Low

$175

Average

—

High

Average target implies +3.56% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Medline Inc.MDLN · NASDAQ-GS